Una actualización en el protocolo en cáncer de próstata metastásico hormonosensible

Álvarez Ossorio, J. L; Rodrigo Aliaga, M; Rodríguez Antolin, A; Unda Urzaiz, M; Calleja, M. Á; Cruz Ruiz, M de la; Blas Quilez, J; Hernández Millán, I. R; Sánchez Zalabardo, D; Cozar Olmo, J. M.
Actas urol. esp ; 47(4): 244-249, mayo 2023. tab
Artículo en Español | IBECS (España) | ID: ibc-219980

Documentos relacionados

  1. Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
  2. Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer.
  3. Metastasis-directed therapy in oligometastatic prostate cancer.
  4. Rational Second-Generation Antiandrogen Use in Prostate Cancer.
  5. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
  6. The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
  7. [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
  8. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
  9. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
  10. Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.